Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai Files Ultra-High Dose Mecobalamin for ALS in Japan
May 29, 2015
- Takeda Launches Once-Weekly DPP-4 Inhibitor Zafatek
May 29, 2015
- Sanofi Files NDA for Antiepileptic Treatment Vigabatrin
May 29, 2015
- Astellas Confident about Achieving FY2017 Japan Sales Target
May 28, 2015
- Asahi Kasei’s New Midterm Plan Aims to Maintain Profitability and Expand Sales in Healthcare Field
May 28, 2015
- Fycompa Receives Positive Opinion from CHMP for Adjunct Therapy for PGTC Seizures: Eisai
May 28, 2015
- Sanofi Oncology Business Unit Head Pascal Rigaudy to Become New President of Genzyme Japan
May 28, 2015
- Astellas’s New 3-Year Plan Targets Sales Growth in Mid-Single-Digit Range
May 27, 2015
- GSK’s Aldreb Debuts as Last Resort for Multidrug Resistant Pseudomonas Aeruginosa Infection
May 26, 2015
- Masanobu Suzuki Tapped as President of Nippon Kayaku
May 26, 2015
- Chugai Files NDA for Combination Psoriasis Vulgaris Drug
May 26, 2015
- Celgene Launches Multiple Myeloma Treatment Pomalyst; Keio Professor Acknowledges Its Efficacy in PFS, OS Improvement
May 26, 2015
- Sales Increase 19.3% for 3 Generic-Only Makers; Incentive for DPC Hospitals Spurs Growth
May 25, 2015
- Ken Masuo to Become Japan Representative for Oncology Business: AZ
May 25, 2015
- Blopress AG Share Tops 60% in Generic Market, Aims for Further Growth: ASKA President Yamaguchi
May 25, 2015
- 180 Billion Yen Sales in FY2017 Is “Quite Reachable”: Meiji Seika Pharma President
May 22, 2015
- Oncologics Retain Top Position in Therapeutic Category Sales Ranking in FY2014: IMS
May 22, 2015
- Japan Pharma Market Down by 0.6% to Under 10 Trillion Yen in FY2014: IMS
May 22, 2015
- Sales of SGLT-2 Inhibitors Were Sluggish in FY2014, but Expected to Pick Up with Lifting of 14-Day Prescription Limit
May 21, 2015
- “4-Company Oligopoly” on Seasonal Flu Vaccines Coming to an End, Era of Mega-Competition Coming to Japan: Dr Yamanishi of BIKEN
May 21, 2015
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…